Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Benchtop Hematology Analyzer Enables Reduction of Manual Review Rates and Processes

By BiotechDaily International staff writers
Posted on 09 May 2013
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
Image: The UniCel DxH 600 — a new benchtop hematology analyzer from Beckman Coulter (Photo courtesy of Beckman Coulter).
A new benchtop hematology cellular analysis system provides laboratories with quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Building on its proven cellular analysis technology to further advance and optimize clinical diagnostic laboratories, Beckman Coulter Inc. (Pasadena, CA, USA) introduces the “UniCel DxH 600” Coulter cellular analysis system, a new benchtop hematology analyzer for mid- to high-volume laboratories. The hematology laboratory’s single most important step, and most time consuming, is the manual review. By reducing manual differential rates, the new analyzer frees labs to focus time on quickly and accurately reporting patient results, improving patient health, and reducing the overall cost of care.

With the same technology, user interface, and consumables as the UniCel DxH 800 Coulter analyzer, the UniCel DxH 600 brings superior standardization of results and process to the hematology laboratory, reducing personnel training and simplifying consumable inventory management. (To further enhance standardization, all new DxH 800 analyzers will be installed with the advanced software; and DxH 800 currently in use will be upgraded.)

The UniCel DxH 600 is equipped with robust software—recently cleared by the US Food and Drug Administration (FDA)—that provides new features, enhancements, and research-use parameters. This advanced software also saves time by allowing labs to partially release patient results manually or automatically via decision rules. It also offers users the ability to create and edit decision rules during instrument operation and offers predefined decision rules using Cell Population Data (for research use only; not for use in diagnostic procedures). Additional features include the ability to track workload by the day, hour, and test, as well as providing automatic notification of STAT samples that have not been processed or released within an expected time frame, helping users to report STAT results efficiently.

"This new hematology analyzer has the ability to transform the hematology lab with unparalleled efficiency, revolutionary scalability, and quality of results,” said John Blackwood, senior vice president, Product Management at Beckman Coulter Diagnostics; “The UniCel DxH 600 advances the technology that [...] will change how labs manage their cellular analysis process.”

Related Links:

Beckman Coulter




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A scheme for the generation of induced pluripotent stem cells (IPSC). (1) Isolate and culture donor cells. (2) Transfect stem cell-associated genes into the cells by viral vectors. Red cells indicate the cells expressing the exogenous genes. (3)  Harvest and culture the cells using mitotically inactivated feeder cells. (4) A small subset of the transfected cells forms iPSC cell colonies (Photo courtesy of Wikimedia Commons).

Innovative Technique Produces More Reliable Pluripotent Stem Cells

A recent paper described a more reliable way to induce the formation of pluripotent stem cells (iPSCs) from adult cells in a mouse model. Reliable high-quality iPSCs are needed for the development of... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.